Diabetes technology company Tandem Diabetes Care (NASDAQ: TNDM) will be reporting earnings this Wednesday after the bell. Here’s what investors should know.
Tandem Diabetes beat analysts’ revenue expectations by 6.8% last quarter, reporting revenues of $234.4 million, up 22.3% year on year. It was a strong quarter for the company, with an impressive beat of analysts’ sales volume estimates and full-year revenue guidance meeting analysts’ expectations.
Is Tandem Diabetes a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Tandem Diabetes’s revenue to grow 6.8% year on year to $237.1 million, slowing from the 13.3% increase it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.40 per share.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Tandem Diabetes has missed Wall Street’s revenue estimates three times over the last two years.
Looking at Tandem Diabetes’s peers in the healthcare technology segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Hims & Hers Health delivered year-on-year revenue growth of 72.6%, missing analysts’ expectations by 1.1%, and Omnicell reported revenues up 5%, topping estimates by 4.9%. Omnicell’s stock price was unchanged following the results.
Read our full analysis of Hims & Hers Health’s results here and Omnicell’s results here.
Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the healthcare technology stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.3% on average over the last month. Tandem Diabetes is down 5.1% during the same time and is heading into earnings with an average analyst price target of $31.10 (compared to the current share price of $15.42).
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
